Foldi, Julia http://orcid.org/0000-0002-7504-867X
Silber, Andrea
Reisenbichler, Emily http://orcid.org/0000-0002-1570-6538
Singh, Kamaljeet
Fischbach, Neal
Persico, Justin
Adelson, Kerin
Katoch, Anamika
Horowitz, Nina
Lannin, Donald
Chagpar, Anees
Park, Tristen
Marczyk, Michal http://orcid.org/0000-0003-2508-5736
Frederick, Courtney
Burrello, Trisha
Ibrahim, Eiman http://orcid.org/0000-0002-7445-6540
Qing, Tao
Bai, Yalai
Blenman, Kim
Rimm, David L. http://orcid.org/0000-0001-5820-4397
Pusztai, Lajos http://orcid.org/0000-0001-9632-6686
Article History
Received: 11 August 2020
Accepted: 23 December 2020
First Online: 8 February 2021
Change Date: 3 February 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41523-022-00392-3
Competing interests
: A.S. has received honoraria and consulting fees from Astra Zeneca. D.L.R. has served as an advisor and consultant for Amgen, Astra Zeneca, Biocept, BMS, Cell Signaling Technology, Cepheid, Daiichi Sankyo, GSK, Konica/Minolta, Merck, NanoString, NextCure, Odonate, Perkin Elmer, PAIGE.AI, Roche, Sanofi, Ventana, and Ultivue; received research funding from Amgen, Cepheid, NavigateBP, NextCure, Konica/Minolta, Lilly, and Ultivue; received instrument support from Akoya/Perkin Elmer, NanoString and Ventana; is a founder and equity holder of PixelGear, and received royalties from Rarecyte. L.P. has received consulting fees and honoraria from Astra Zeneca, Merck, Novartis, Bristol-Myers Squibb Genentech, Eisai, Pieris, Immunomedics, Seattle Genetics, Clovis, Syndax, H3Bio, and Daiichi. The remaining authors declare no competing interests.